Polatuzumab Vedotin — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

2 Recruiting

9 Completed trials

9 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II: 5 Phase I/II: 3

Oversight events:

1 serious breach 12 unexpected events across 3 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 3 B-cell lymphoma refractory 2 Diffuse large B-cell lymphoma refractory 2 Diffuse large B-cell lymphoma recurrent 2 Diffuse large B-cell lymphoma stage II 1 B-cell lymphoma 1 Diffuse large B-cell lymphoma stage I 1 High-grade B-cell lymphoma 1 B-cell unclassifiable lymphoma high grade 1 Diffuse large B-cell lymphoma stage IV 1 Diffuse large B-cell lymphoma stage III 1 B-cell lymphoma recurrent 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 4 AbbVie Deutschland GmbH & Co. KG 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 GWT-Tud GmbH 1 Instytut Hematologii I Transfuzjologii 1 Medical University Of Vienna 1 Merck Sharp & Dohme LLC 1 Miltenyi Biomedicine GmbH 1 Region Skane 1

All trials

12 total

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending

2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Phase II 5 countries Merck Sharp & Dohme LLC
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting

2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
DALY 2-EU Ended

2023-506270-13-00 Phase II 15 countries Miltenyi Biomedicine GmbH
POLAR BEAR Ended

2022-502887-19-00 Phase III 6 countries Region Skane
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma Ended

2024-518704-41-00 Phase II 1 country Medical University Of Vienna
Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus… Ended

2023-508259-38-00 Phase III 3 countries GWT-Tud GmbH
A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX)… Ended

2024-512537-33-00 Phase III 5 countries F. Hoffmann-La Roche AG
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (… Ended

2024-516904-40-00 Phase III 8 countries F. Hoffmann-La Roche AG

Showing 1–12 of 12 trials

← All drugs A–Z